Who is sponsoring NCT06693817?

NCT06693817 is sponsored by Guilherme Sant'Anna, MD.

What condition does NCT06693817 study?

NCT06693817 studies Sudden Unexplained Infant Death, Apnea of Newborn, Newborn Morbidity, Newborn Asphyxia, Birth Outcome, Adverse, Birth Asphyxia, Pregnancy Related, Newborn; Vitality, ECG Electrode Site Reaction, Infant ALL, Infant Death, Infant, Newborn, Diseases, Infant Apnea, Infant Conditions, Parents, Delivery Problem for Fetus, Delivery Complication.

Is NCT06693817 still recruiting?

NCT06693817 is currently recruiting now. Last updated 17 April 2025.

Last reviewed 2025-04-17 · How we verify

NCT06693817: AWARD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Advanced Wireless Sensors for Neonatal Care in the Delivery Room

Recruiting now NA Last updated 17 April 2025

What this trial tests

NA trial testing Wireless skin sensors vital sign monitoring system in Sudden Unexplained Infant Death in 600 participants. Currently enrolling.

Timeline

8 April 2025

Primary endpoint
30 July 2026

30 June 2027

Quick facts

Lead sponsor	Guilherme Sant'Anna, MD
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	other
Enrollment	600
Start date	8 April 2025
Primary completion	30 July 2026
Estimated completion	30 June 2027
Sites	7 locations across Zimbabwe, Argentina, Canada, Mozambique, Brazil

Drugs / interventions tested

Wireless skin sensors vital sign monitoring system
Wired vital sign monitoring system

Conditions studied

Sudden Unexplained Infant Death — all drugs for Sudden Unexplained Infant Death →
Apnea of Newborn — all drugs for Apnea of Newborn →
Newborn Morbidity — all drugs for Newborn Morbidity →
Newborn Asphyxia — all drugs for Newborn Asphyxia →

Sponsor

Guilherme Sant'Anna, MD

Who can join

Adults 35 Weeks to 42 Weeks, any sex, with Sudden Unexplained Infant Death or Apnea of Newborn. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goals of this observational study is to assess whether a new advanced wireless skin sensor vital sign monitoring system can effectively monitor the vital signs of healthy newborn infants (≥ 35 weeks gestational age). The main aims of this Study are to: 1. Assess feasibility 2. Evaluate safety 3. Determine accuracy of the wireless monitoring system, compared to the standard of care wired vital sign monitoring system, immediately after delivery and for the first 2h of age in the obstetrical center under unsupervised parents' care. The newborn infants participating in the Study will have both vital sign monitoring systems placed on their chest and limb. Their vital signs will be monitored for 2h consecutively.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Sudden Unexplained Infant Death

Currently open trials in the same condition.

NCT05503771 — Improving Pediatrician Counseling About Infant Safe Sleep Using the Electronic Medical Record · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06693817 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Guilherme Sant'Anna, MD
Last refreshed: 17 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06693817.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing